SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002; 82: 373428.
  • 2
    Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003; 29(Suppl 1): 3-93-9.
  • 3
    Almond JB, Cohen GM. The proteasome: a novel target for cancer chemotherapy. Leukemia. 2002; 16: 433443.
  • 4
    Etlinger JD, Goldberg AL. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes. Proc Natl Acad Sci USA. 1977; 74: 5458.
  • 5
    Matthews W, Driscoll J, Tanaka K, Ichihara A, Goldberg AL. Involvement of the proteasome in various degradative processes in mammalian cells. Proc Natl Acad Sci USA. 1989; 86: 25972601.
  • 6
    Delcros JG, Floc'h MB, Prigent C, Arlot-Bonnemains Y. Proteasome inhibitors as therapeutic agents: current and future strategies. Curr Med Chem. 2003; 10: 479503.
  • 7
    Kloetzel PM. The proteasome and MHC Class I antigen processing. Biochim Biophys Acta. 2004; 1695: 225233.
  • 8
    Bedi A, Kastan MB. Regulation of the cell cycle. In: AbeloffMD, ArmitageJO, LichterAS, NiederhuberJE, editors. Clinical oncology, 2nd ed. New York: Churchill-Livingstone, 2000: 1028.
  • 9
    Salvat C, Aquaviva C, Jariel-Encontre I, et al. Are there multiple proteolytic pathways contributing to c-Fos, c-Jun and p53 protein degradation in vivo? Mol Biol Rep. 1999; 26: 4551.
  • 10
    Bedi A, Mookerjee B. Biological significance and molecular mechanisms of p53-induced apoptosis. Apoptosis. 1998; 3: 237244.
  • 11
    Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995; 55: 51875190.
  • 12
    Voorhees PM, Dees EC, O'Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res. 2003; 9: 63166325.
  • 13
    Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002; 7: 916.
  • 14
    Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002; 2: 301310.
  • 15
    Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59: 26152622.
  • 16
    Ling YH, Liebes L, Ng B, et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther. 2002; 1: 841849.
  • 17
    Ling YH, Liebes L, Jiang JD, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res. 2003; 9: 11451154.
  • 18
    Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003; 9: 11361144.
  • 19
    Russo SM, Tepper JE, Baldwin AS Jr., et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001; 50: 183193.
  • 20
    Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001; 61: 30713076.
  • 21
    Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003; 101: 23772380.
  • 22
    Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002; 277: 1663916647.
  • 23
    Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 2002; 99: 1437414379.
  • 24
    LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002; 62: 49965000.
  • 25
    Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998; 102: 11151123.
  • 26
    Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol. 2002; 20: 44204427.
  • 27
    Aghajanian C, Soignet S, Dizon DS, et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002; 8: 25052511.
  • 28
    Richardson PG, Barlogie B, Berenson J, et al. A Phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003; 348: 26092617.
  • 29
    Jagannath S, Barlogie B, Berenson J, et al. A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 2004; 127: 165172.
  • 30
    Richardson P, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Eng J Med. 2005; 353: 24872498.
  • 31
    Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood. 2005; 15: 30583065.
  • 32
    Berenson J, Yang H, Swift R, et al. A Phase I/II trial of VELCADE and melphalan combination therapy (Vc+M) for patients with relapsed or refractory multiple myeloma (MM) [abstract 209]. Blood. 2004; 104: 64a.
  • 33
    Hollmig K, Stover J, Talamo G, et al. Addition of bortezomib (Velcade™) to high dose melphalan (Vel-Mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM) [abstract 929]. Blood. 2004; 104: 266a.
  • 34
    Chanan-Khan A, Miller KC, McCarthy P, et al. A Phase II study of Velcade (V), Doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients (pts) with relapsed (rel) or refractory (ref) multiple myeloma (MM) and Waldenstrom's macroglobulinemia (WM): encouraging preliminary results. Blood. 2004; 104: 665a666a.
  • 35
    Zangari M, Barlogie B, Hollmig K, et al. Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM). Blood. 2004; 104: 413a414a.
  • 36
    Giralt S, Aleman A, Lei X, et al. Results of bortezomib (BTZ) therapy for myeloma (MM) patients relapsing after an allogeneic transplant [abstract 1916]. Blood. 2004; 104: 459a.
  • 37
    Jagannath S, Richardson P, Barlogie B, et al. Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone [abstract 2341]. Proc Am Soc Clin Oncol. 2003; 22: 582.
  • 38
    Richardson PG, Chanan-Khan A, Schlossman RL, et al. Phase II trial of single agent bortezomib (VELCADE) in patients with previously untreated multiple myeloma (MM) [abstract 336]. Blood. 2004; 104: 100a.
  • 39
    Jagannath S, Wolf JL, Camacho E, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol. 2005; 127: 165172.
  • 40
    Harousseau J, Attal M, Leleu X, et al. Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM Phase II study [abstract 1490]. Blood. 2004; 104: 416a.
  • 41
    Cavenagh J, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma [abstract 1478]. Blood. 2004; 104: 413a.
  • 42
    Alexanian R, Wang LW, Weber DM, Delasalle KB. VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma [abstract 210]. Blood. 2004; 104: 64a.
  • 43
    Mateos MV, Blade J, Diaz Mediavilla J, et al. A Phase I/II national, multicenter, open-label study of bortezomib plus melphalan and prednisone (V-MP) in elderly untreated multiple myeloma patients [abstract 3462]. Blood. 2004; 104: 943a.
  • 44
    Gatto S, Scappini B, Pham L, et al. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 2003; 88: 853863.
  • 45
    Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002; 62: 10831086.
  • 46
    Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res. 2004; 10: 33713376.
  • 47
    Attar EC, DeAngelo DJ, Ballen KK, et al. Phase I dose escalating trial of bortezomib (VELCADE) in combination with idarubicin and cytarabine in patients with acute myeloid leukemia. Blood. 2004; 104: 498a499a.
  • 48
    Faderl S, Rai KR, Gribben J, et al. Phase 2 study of three doses of single agent bortezomib in patients with fludarabine-refractory B-cell CLL [abstract 484]. Blood. 2004; 104: 293b.
  • 49
    Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 667675.
  • 50
    O'Connor OA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2005; 23: 676684.
  • 51
    Belch A, Kouroukis T, Crump M, et al. Phase II trial of bortezomib in mantle cell lymphoma. Blood. 2004; 104: 175a176a.
  • 52
    Chen CI, White D, Kouroukis CT, et al. Antitumor activity of bortezomib (PS-341; Velcade) in a Phase II study of patients with previously untreated or treated Waldenstrom's macroglobulinemia (WM) [abstract]. Blood. 2004; 104: 896a.
  • 53
    Dunleavy K, Janik J, Gea-Banacloche J, et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma [abstract 1386]. Blood. 2004; 104: 389a.
  • 54
    Younes A, Pro B, Romaguera J, Dang N. Safety and efficacy of bortezomib (Velcade) for the treatment of relapsed classical Hodgkin's disease [abstract 2641]. Blood. 2004; 104: 722a.
  • 55
    Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol. 2003; 171: 8895.
  • 56
    Chauhan D, Li G, Shringarpure R, et al. Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003; 63: 61746177.
  • 57
    Ling YH, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation and mitochondrial dysfunction in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003; 278: 3371433723.
  • 58
    Denlinger CE, Rundall BK, Keller MD, Jones DR. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg. 2004; 78: 12071214.
  • 59
    Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther. 2003; 2: 835843.
  • 60
    Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res. 2001; 100: 1117.
  • 61
    Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 2001; 82: 110122.
  • 62
    Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001; 7: 14191428.
  • 63
    Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res. 2000; 6: 37193728.
  • 64
    Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res. 1999; 5: 26382645.
  • 65
    Cusack JC Jr., Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001; 61: 35353540.
  • 66
    Appleman LJ, Ryan DP, Clark JW, et al. Phase I dose escalation study with bortezomib and gemcitabine safety and tolerability in patients with advanced solid tumors [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 209a.
  • 67
    Albanell J, Baselga J, Guix M, et al. Phase I study of bortezomib in combination with docetaxel in anthracycline-pretreated advanced breast cancer [abstract 63]. Proc Am Soc Clin Oncol. 2003; 22: 16.
  • 68
    Davis NB, Taber DA, Ansari RH, et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago Phase II consortium study. J Clin Oncol. 2004; 22: 115119.
  • 69
    Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol. 2004; 22: 37203725.
  • 70
    Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol. 2004; 22: 21082121.
  • 71
    Blaney SM, Bernstein M, Neville K, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004; 22: 48044809.
  • 72
    Fanucchi MP, Belt RJ, Fossella FV, et al. Phase (ph) 2 study of bortezomib ± docetaxel in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC). Preliminary results [abstract 7107]. J Clin Oncol. 2004; 22(Suppl 14S): 643s.
  • 73
    Davies AM, Lara PN, Lau D, et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (gem) and carboplatin (carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Consirtium study [abstract 7106]. J Clin Oncol. 2004; 22(Suppl 14S): 642s.
  • 74
    Stevenson J, Nho CW, Johnson SW, et al. Phase II/pharmacodynamic trial of PS-341 (bortezomib, VELCADE®) in advanced non-small cell lung cancer [abstract]. J Clin Oncol. 2004; 22(Suppl 14S): 652s.
  • 75
    Ryan DP, O'Neil B, Lima CR, et al. Phase I dose escalation study of the proteasome inhibitor, bortezomib, plus irinotecan in patients with advanced solid tumors [abstract]. Proc Am J Clin Oncol. 2003; 22: 228.
  • 76
    Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol. 2004; 130: 623625.
  • 77
    Millennium Pharmaceuticals, Inc. VELCADE (bortezomib) for injection. Cambridge, MA: Millenium Pharmaceuticals, Inc., year. Full prescribing information available at URL:http://www.millennium.com/products/velcade/indexasp (accessed August 31, 2005].
  • 78
    Lonial S, Waller EK, Richardson PG, et al. Evaluation of the severity and risk of thrombocytopenia with bortezomib therapy in relapsed and refractory multiple myeloma [abstract 371]. Hematol J. 2004; 5: S130S131.
  • 79
    Richardson PG, Briemberg H, Jagannath S, et al. Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE). The SUMMIT and CREST Study Group [abstract 368]. Hematol J. 2004; 5: S129.